Kim Blenman, PhD, MS
Research & Publications
Biography
News
Research Summary
To date, the major challenge in studies of the tumor microenvironment has been the lack of tools to interrogate the tumor microenvironment in situ. Major technical components of my research involve flow cytometry, histology, and creation of imaging software tools. Flow cytometry is an elegant quantitative approach to identifying the contents of the tumor microenvironment. However, to understand the spatial relationships of the cells and structures in the tumor microenvironment we must assess the space in situ by histology. One of our short-term goals is to change the way that we approach histology by making it fully quantitative and use the approach to generate clinically meaningful results for use in standard of care settings and clinical trials. Therefore, for the past several years we have been working on creating tools as part of our long-term research goal.
We create immune profiles using high dimensional multiplex histology (immunohistochemistry (IHC); immunofluorescence (IF)) assessment of cell characteristics, distributions, spatial relationships/interactions, and target antigen intensities at the single cell level as well as the global level. Our histology method allows for multiplexed staining of up to 8 biomarkers with chromogen-based IHC and at least 20 biomarkers with pure fluorochrome-based IF per tissue section through dye inactivation. Any entities that can be stained through histology can be evaluated using our method (e.g. proteins (secreted; membrane-bound), RNA, DNA, metabolites, etc.).
Quantitative imaging analysis can be performed successfully on any image taken from any standard microscopy system. However, quantitative imaging systems, such as the Vectra Multispectral Imaging System (CRi/Perkin Elmer) and the TissueFAXS RGB Imaging System (TissueGnostics), in which I am an expert and have helped to develop both, provide all-in-one tools for automated imaging and analysis. The quantitative analysis is performed using algorithms and scripts developed using commercial (InForm/Nuance; StrataQuest; MATLAB) software. The algorithms and scripts lead to identification and segmentation (e.g. nucleus, cytoplasm, and membrane) of each cell and/or tissue structure by target antigens tagged with chromogens/fluorochromes. From this data, we can enumerate each cell/structure type, calculate the cell/structure population distributions, determine target antigen intensities, identify spatial relationships between cells and/or structures, and correlate this information with clinical parameters/outcomes and therapeutic response.
Since the approval of the first checkpoint inhibitor in 2011, the interest in and value of the immune system in disease and treatment has skyrocketed. Approaches, such as the methods that we have created, that allows one to fully interrogate the relationships of components in disease microenvironments and use the knowledge to guide and/or create treatment are the future of medicine.
Extensive Research Description
Computational Histology and spatial analysis tools. As the number of visible objects in an image increases, the ability of the human brain to discern patterns in the image decreases. We endeavor to use our software tools to help the human brain identify patterns in high complexity microenvironments and link those patterns to the biology of disease, clinical data, therapeutic response, and health disparity.
Software tools for in silico analysis of images: We currently define the approach that we use to capture the in situ profiles of the tissue microenvironment as Computational Histology. We use standard microscopy to capture multiplexed histology images of up to 20 biomarkers per tissue slide. Since the biomarkers are imaged at different time periods, they can be recombined in silico to study any combination and/or coexpressions of the biomarkers.
To capture the profile of tissue microenvironments, we created algorithms that align the images into a composite image, isolate each cell in the composite image, and identify the positive cells in the composite image. The information collected is used for our recently developed novel image analysis tools for spatial relationships. The tools incorporate methods and metrics used in flow cytometry to create histograms, dot scatterplots, backgates, and cluster/pattern plots for isolation, identification, quantitation, and measurement of spatial relationships of single cells, cell populations, and clusters/patterns of cells. Our method and workflow were recently published in Cytometry A journal and received the honor of being featured on the cover of the journal.
Using some or all aspects of our Computational Histology approach we have found that B cells and neutrophils may have a role in tumor regression in melanoma and breast cancer. In melanoma, we used a mouse tumor regression model that consisted of implanting immunocompetent B6 mice with YUMMER1.7 melanoma cells. We found that B cells including plasmablasts and plasma cells and neutrophils were numerous and increased with the introduction of immunotherapy. Neutrophils were in direct contact with dead or dying melanoma cells and immunotherapy caused neutrophil extracellular traps (NETs)-like formations as well as geographic necrosis. In the clinic, we found that patients that were treated with anti-PD-1 (pembrolizumab; nivolumab) who had high levels of B cells had better progression-free survival.
In breast cancer, we found that sentinel lymph node B cells in patients could predict disease-free survival. Breast cancer patients with higher density of B cells had longer disease-free survival. This benefit was also seen in patients with the triple-negative subtype which is the breast cancer with pathologic complete response rates of 20% to 60% with chemotherapy treatment. Patients that achieve pathologic complete response are less likely to have a distant metastasis. It is also the breast cancer subtype that is more common in premenopausal women of African descent. Overall, our data suggests that B cells may protect against cancer recurrence and potentially distant metastasis.
Earlier Research in Autoimmunity
Generation and phenotypic characterization of a murine model of systemic lupus erythematosus (SLE). SLE is an autoimmune disease characterized by production of autoantibodies against self-nuclear proteins. In the most severe form of SLE, the autoantibody:antigen complexes bind to the basement membrane of kidneys initiating a cascade of events that lead to renal failure. We created congenic mouse strains of SLE-susceptibility genes from the SLE-prone NZM2410 mouse strain on a B6 background. We used a speed-congenic approach, which cut the development time in half. Each of the 4 congenic and multiple sub-congenic strains have unique phenotypes that when recombined together in bi- and tri- congenics was successful in partially or fully reconstituting the original disease. We bred the congenic strains, genotyped, and phenotyped them. The speed congenic approach is used by essentially all labs that are using genetics and mice to address their research questions. Our congenic mice are available to the research community through the Jackson Labs.
Cytokine modulation as a potential key to treatment of SLE. We and others have shown that cytokines are required to keep autoimmune cells alive by inhibition of apoptosis and perpetuation of inflammation. We have shown that there are defects in the TNFα/TNFR1 apoptotic signaling pathway in lupus-prone mice post binding of TNFα to TNFR1. We have also shown that gene-therapy treatment with IL-10 reduces inflammation and delays renal damage in lupus-prone mice.
Coauthors
Research Interests
Algorithms; Breast Neoplasms; Computer Graphics; Head and Neck Neoplasms; Image Processing, Computer-Assisted; Immunotherapy; Medical Informatics Computing; Melanoma; Multiple Myeloma; Clinical Trial; Data Visualization; Multiomics
Public Health Interests
Bioinformatics; Biomarkers; Cancer; Clinical Trials; Immunology; Pharmaceuticals and Medical Devices
Research Images
Selected Publications
- Abstract P1-04-12: Systemic immune response to a Phase I/II trial of Durvalumab concomitant with neoadjuvant chemotherapy in early stage TNBCBlenman K, Marczyk M, Foldi J, Gunasekharan V, Silber A, Pusztai L. Abstract P1-04-12: Systemic immune response to a Phase I/II trial of Durvalumab concomitant with neoadjuvant chemotherapy in early stage TNBC Cancer Research 2023, 83: p1-04-12-p1-04-12. DOI: 10.1158/1538-7445.sabcs22-p1-04-12.
- Abstract PD9-09: Molecular differences between younger versus older estrogen receptor positive/human epidermal growth factor receptor-2 negative breast cancersQing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan N, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Abstract PD9-09: Molecular differences between younger versus older estrogen receptor positive/human epidermal growth factor receptor-2 negative breast cancers Cancer Research 2023, 83: pd9-09-pd9-09. DOI: 10.1158/1538-7445.sabcs22-pd9-09.
- Molecular differences between younger versus older ER-positive and HER2-negative breast cancersQing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan N, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers Npj Breast Cancer 2022, 8: 119. PMID: 36344517, PMCID: PMC9640562, DOI: 10.1038/s41523-022-00492-0.
- Leveraging the Dynamic Immune Environment Triad in Patients with Breast Cancer: Tumour, Lymph Node, and Peripheral BloodWall I, Boulat V, Shah A, Blenman KRM, Wu Y, Alberts E, Calado DP, Salgado R, Grigoriadis A. Leveraging the Dynamic Immune Environment Triad in Patients with Breast Cancer: Tumour, Lymph Node, and Peripheral Blood Cancers 2022, 14: 4505. PMID: 36139665, PMCID: PMC9496983, DOI: 10.3390/cancers14184505.
- PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancerRozenblit M, Blenman K, Harigopal M, Reisenbichler E, Singh K, Qing T, Ibrahim E, Ramkissoon S, Asmelash S, Lin HK, Roberts M, Ross J, Huang RSP, Pusztai L. PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer Breast Cancer Research And Treatment 2022, 196: 221-227. PMID: 36028784, DOI: 10.1007/s10549-022-06712-2.
- Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.
- Pilot study to evaluate tools to collect pathologist annotations for validating machine learning algorithmsElfer K, Dudgeon S, Garcia V, Blenman K, Hytopoulos E, Wen S, Li X, Ly A, Werness B, Sheth MS, Amgad M, Gupta R, Saltz J, Hanna MG, Ehinger A, Peeters D, Salgado R, Gallas BD. Pilot study to evaluate tools to collect pathologist annotations for validating machine learning algorithms Journal Of Medical Imaging 2022, 9: 047501-047501. PMID: 35911208, PMCID: PMC9326105, DOI: 10.1117/1.jmi.9.4.047501.
- Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancerMarczyk M, Qing T, O’Meara T, Yagahoobi V, Pelekanou V, Bai Y, Reisenbichler E, Cole KS, Li X, Gunasekharan V, Ibrahim E, Fanucci K, Wei W, Rimm DL, Pusztai L, Blenman KRM. Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer Npj Breast Cancer 2022, 8: 88. PMID: 35869114, PMCID: PMC9307813, DOI: 10.1038/s41523-022-00449-3.
- Abstract 460: Tools for collecting pathologist annotations and understanding interobserver variabilityElfer K, Blenman K, Dudgeon S, Garcia V, Ehinger A, Li X, Ly A, Peeters D, Werness B, Hanna M, Salgado R. Abstract 460: Tools for collecting pathologist annotations and understanding interobserver variability Cancer Research 2022, 82: 460-460. DOI: 10.1158/1538-7445.am2022-460.
- Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm D, Pusztai L. Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC. Journal Of Clinical Oncology 2022, 40: 516-516. DOI: 10.1200/jco.2022.40.16_suppl.516.
- Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements.Blenman K, Fanucci K, Bai Y, Pelekanou V, Nahleh Z, Shafi S, Burela S, Barlow W, Sharma P, Thompson A, Godwin A, Rimm D, Hortobagyi G, Pusztai L. Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements. Journal Of Clinical Oncology 2022, 40: 594-594. DOI: 10.1200/jco.2022.40.16_suppl.594.
- Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysisHercules SM, Alnajar M, Chen C, Mladjenovic SM, Shipeolu BA, Perkovic O, Pond GR, Mbuagbaw L, Blenman KR, Daniel JM. Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis BMJ Open 2022, 12: e055735. PMID: 35623750, PMCID: PMC9150263, DOI: 10.1136/bmjopen-2021-055735.
- Development of Training Materials for Pathologists to Provide Machine Learning Validation Data of Tumor-Infiltrating Lymphocytes in Breast CancerGarcia V, Elfer K, Peeters DJE, Ehinger A, Werness B, Ly A, Li X, Hanna MG, Blenman KRM, Salgado R, Gallas BD. Development of Training Materials for Pathologists to Provide Machine Learning Validation Data of Tumor-Infiltrating Lymphocytes in Breast Cancer Cancers 2022, 14: 2467. PMID: 35626070, PMCID: PMC9139395, DOI: 10.3390/cancers14102467.
- Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancerHercules SM, Liu X, Bassey-Archibong BBI, Skeete DHA, Smith Connell S, Daramola A, Banjo AA, Ebughe G, Agan T, Ekanem IO, Udosen J, Obiorah C, Ojule AC, Misauno MA, Dauda AM, Egbujo EC, Hercules JC, Ansari A, Brain I, MacColl C, Xu Y, Jin Y, Chang S, Carpten JD, Bédard A, Pond GR, Blenman KRM, Manojlovic Z, Daniel JM. Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer Cancer Causes & Control 2022, 33: 831-841. PMID: 35384527, PMCID: PMC9085672, DOI: 10.1007/s10552-022-01574-x.
- Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clinical Cancer Research 2022, 28: 2587-2597. PMID: 35377948, PMCID: PMC9464605, DOI: 10.1158/1078-0432.ccr-21-3215.
- Strategies to mitigate the toxicity of cancer therapeuticsKahn AM, Blenman KRM, Sonis ST, Lustberg MB. Strategies to mitigate the toxicity of cancer therapeutics 2022, 155: 215-244. PMID: 35779875, DOI: 10.1016/bs.acr.2022.02.006.
- Comprehensive Analysis of Metabolic Isozyme Targets in Cancer.Marczyk M, Gunasekharan V, Casadevall D, Qing T, Foldi J, Sehgal R, Shan NL, Blenman KRM, O'Meara TA, Umlauf S, Surovtseva YV, Muthusamy V, Rinehart J, Perry RJ, Kibbey R, Hatzis C, Pusztai L. Comprehensive Analysis of Metabolic Isozyme Targets in Cancer. Cancer Research 2022, 82: 1698-1711. PMID: 35247885, DOI: 10.1158/0008-5472.can-21-3983.
- Abstract P2-08-03: PD-L1 protein expression in relation to Recurrence Score values in early stage ER+HER2- breast cancerBlenman K, Harigopal M, Huang R, Reisenbichler E, Qing T, Ibrahim E, Singh K, Ramkissoon S, Mustimbo R, Ross J, Pusztai L. Abstract P2-08-03: PD-L1 protein expression in relation to Recurrence Score values in early stage ER+HER2- breast cancer Cancer Research 2022, 82: p2-08-03-p2-08-03. DOI: 10.1158/1538-7445.sabcs21-p2-08-03.
- Abstract TF2-1: A journey through the life of HER2: How did we get here and where are we going?Blenman K. Abstract TF2-1: A journey through the life of HER2: How did we get here and where are we going? Cancer Research 2022, 82: tf2-1-tf2-1. DOI: 10.1158/1538-7445.sabcs21-tf2-1.
- Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancerFoldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer Npj Breast Cancer 2022, 8: 17. PMID: 35115541, PMCID: PMC8814070, DOI: 10.1038/s41523-022-00392-3.
- Abstract PO-142: Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancerHercules S, Liu X, Bassey-Archibong B, Skeete D, Connell S, Daramola A, Banjo A, Ebughe G, Agan T, Ekanem I, Udosen J, Obiorah C, Ojule A, Misauno M, Dauda A, Egbujo E, Hercules J, Ansari A, Brain I, MacColl C, Xu Y, Jin Y, Chang S, Carpten J, Bédard A, Pond G, Blenman K, Manojlovic Z, Daniel J. Abstract PO-142: Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer Cancer Epidemiology Biomarkers & Prevention 2022, 31: po-142-po-142. DOI: 10.1158/1538-7755.disp21-po-142.
- Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control studyYaghoobi V, Moutafi M, Aung TN, Pelekanou V, Yaghoubi S, Blenman K, Ibrahim E, Vathiotis IA, Shafi S, Sharma A, O’Meara T, Fernandez AI, Pusztai L, Rimm DL. Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control study Breast Cancer Research 2021, 23: 113. PMID: 34906209, PMCID: PMC8670126, DOI: 10.1186/s13058-021-01493-w.
- KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelementsZhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, McGeary MK, Song E, Blenman KRM, Micevic G, Jessel S, Zhang Y, Yin M, Booth CJ, Jilaveanu LB, Damsky W, Sznol M, Kluger HM, Iwasaki A, Bosenberg MW, Yan Q. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements Nature 2021, 598: 682-687. PMID: 34671158, PMCID: PMC8555464, DOI: 10.1038/s41586-021-03994-2.
- A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast CancerIwase T, Blenman KRM, Li X, Reisenbichler E, Seitz R, Hout D, Nielsen TJ, Schweitzer BL, Bailey DB, Shen Y, Zhang X, Pusztai L, Ueno NT. A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer Cancers 2021, 13: 4839. PMID: 34638323, PMCID: PMC8508147, DOI: 10.3390/cancers13194839.
- Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast CancerMHC-II Is an Immunotherapy Biomarker in Early Breast CancerGonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, Sun X, Axelrod ML, Sheng Q, Luo N, Gomez H, Sanchez V, Sanders M, Pusztai L, Petricoin E, Blenman K, Balko JM, Institute A, Leyland-Jones B, Agency C, Chia S, Serpanchy R, Yu C, University E, McMillan S, Mosley R, Nguyen K, Wood E, Zelnak A, University G, Dillis C, Donnelly R, Harrington T, Isaacs C, Kallakury B, Liu M, Lynce F, Oppong B, Pohlmann P, Tousimis E, Warren R, Willey S, Wong J, Zeck J, Center L, Albain K, Bartolotta M, Bova D, Brooks C, Busby B, Czaplicki K, Duan X, Gamez R, Ganesh K, Gaynor E, Godellas C, Grace-Louthen C, Kuritza T, Lo S, Nagamine A, Perez C, Robinson P, Rosi D, Vaince F, Ward K, Hospital I, Choquette K, Edmiston K, Gallimore H, McGovern J, Mokarem K, Pajaniappan M, Rassulova S, Scott K, Sherwood K, Wright J, Clinic A, Anderson K, Gray R, Myers S, Northfelt D, Pockaj B, Roedig J, Wasif N, Clinic R, Arens A, Boughey J, Brandt K, Carroll J, Chen B, Connors A, Degnim A, Farley D, Greenlee S, Haddad T, Hieken T, Hobday T, Jakub J, Liberte L, Liu M, Loprinzi C, Menard L, Moe M, Moynihan T, O'Sullivan C, Olson E, Peethambaram P, Ruddy K, Russell B, Rynearson A, Smith D, Visscher D, Windish A, Institute H, Cox K, Dawson K, Newton O, Ramirez W, University O, Bengtson H, Bucher J, Chui S, Gilbert-Ghormley B, Hampton R, Kemmer K, Kurdyla D, Nauman D, Spear J, Wilson A, Institute S, Beatty D, Dawson P, Ellis E, Fer M, Hanson J, Goetz M, Haddad T, Iriarte D, Kaplan H, Porter B, Rinn K, Thomas H, Thornton S, Tickman R, Varghis N, Birmingham U, Caterinichia V, Santos J, Falkson C, Forero A, Krontiras H, Vaklavas C, Wei S, University of Arizona, Bauland A, Inclan L, Lewallen D, Powell A, Roney C, Schmidt K, Viscusi R, Wright H, San Diego University of California, Blair S, Boles S, Bykowski J, Datnow B, Densley L, Eghtedari M, Genna V, Hasteh F, Helsten T, Kormanik P, Ojeda-Fournier H, Onyeacholem I, Parker B, Podsada K, Schwab R, Wallace A, Yashar C, San Francisco University of California, Alvarado M, Au A, Balassanian R, Benz C, Buxton M, Chen Y, Chien J, D'Andrea C, Davis S, Esserman L, Ewing C, Goga A, Hirst G, Hwang M, Hylton N, Joe B, Lyandres J, Kadafour M, Krings G, Melisko M, Moasser M, Munter P, Ngo Z, Park J, Price E, Rugo H, Veer L, Wong J, Yau C, University of Chicago, Abe H, Jaskowiak N, Nanda R, Olopade F, Schacht D, University of Colorado D, Borges V, Colvin T, Diamond J, Elias A, Finlayson C, Fisher C, Hardesty L, Kabos P, Kounalakis N, Mayordomo J, McSpadden T, Murphy C, Rabinovitch R, Sams S, Shagisultanova E, University of Kansas, Baccaray S, Khan Q, University of Minnesota, Beckwith H, Blaes A, Emory T, Haddad T, Hui J, Klein M, Kuehn-Hajder J, Nelson M, Potter D, Tuttle T, Yee D, Zera R, University of Pennsylvania, Bayne L, Bradbury A, Clark A, DeMichele A, Domchek S, Fisher C, Fox K, Frazee D, Lackaye M, Matro J, McDonald E, Rosen M, Shah P, Tchou J, Volpe M, Center U, Alvarez R, Barcenas C, Berry D, Booser D, Brewster A, Brown P, Gonzalez-Angulo A, Ibrahim N, Karuturi M, Koenig K, Moulder S, Murray J, Murthy R, Pusztai L, Saigal B, Symmans W, Tripathy D, Theriault R, Ueno N, Valero V, California U, Brown M, Carranza M, Flores Y, Lang J, Luna A, Perez N, Tripathy D, Watkins K, Center U, Armstrong S, Boyd C, Chen L, Clark V, Frankel A, Euhus D, Froehlich T, Goudreau S, Haley B, Harker-Murray A, Klemow D, Leitch A, Leon R, Li H, Morgan T, Qureshi N, Rao R, Reeves M, Rivers A, Sadeghi N, Seiler S, Staves B, Tagoe V, Thomas G, Tripathy D, Unni N, Weyandt S, Wooldridge R, Zuckerman J, Universty of Washington, Korde L, Griffin M, Butler B, Cundy A, Rubinstein L, Hixson C. Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast CancerMHC-II Is an Immunotherapy Biomarker in Early Breast Cancer Clinical Cancer Research 2021, 27: 5299-5306. PMID: 34315723, PMCID: PMC8792110, DOI: 10.1158/1078-0432.ccr-21-0607.
- Characterization of the tumor immune microenvironment of triple-negative breast cancer (TNBC) patients who self-identify as African American (AA) or non-African American (NonAA).Blenman K, Marczyk M, Qing T, O'Meara T, Yaghoobi V, Pelekanou V, Bai Y, Reisenbichler E, Li X, Gunasekharan V, Ibrahim E, Rimm D, Pusztai L, Cole K. Characterization of the tumor immune microenvironment of triple-negative breast cancer (TNBC) patients who self-identify as African American (AA) or non-African American (NonAA). Journal Of Clinical Oncology 2021, 39: 564-564. DOI: 10.1200/jco.2021.39.15_suppl.564.
- Abstract PS19-05: Functional importance of long-tail mutations in breast cancerQing T, Mohsen H, Rozenblit M, Marczyk M, Foldi J, Blenman K, Gunasekharan V, Pusztai L. Abstract PS19-05: Functional importance of long-tail mutations in breast cancer Cancer Research 2021, 81: ps19-05-ps19-05. DOI: 10.1158/1538-7445.sabcs20-ps19-05.
- Abstract PS5-08: Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancersRozenblit M, Huang R, Danziger N, Alexander B, Ramkissoon S, Blenman K, Ross J, Rimm D, Pusztai L. Abstract PS5-08: Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers Cancer Research 2021, 81: ps5-08-ps5-08. DOI: 10.1158/1538-7445.sabcs20-ps5-08.
- Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis TherapyLo YC, Price C, Blenman K, Patil P, Zhang X, Robert ME. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy American Journal Of Clinical Pathology 2021, 156: 214-228. PMID: 33555016, DOI: 10.1093/ajcp/aqaa217.
- Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancerFoldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer Npj Breast Cancer 2021, 7: 9. PMID: 33558513, PMCID: PMC7870853, DOI: 10.1038/s41523-021-00219-7.
- Abstract PR12: Dynamic clustering of cancer genomics datasets beyond pre-defined human categoriesMohsen H, Blenman K, Pusztai L. Abstract PR12: Dynamic clustering of cancer genomics datasets beyond pre-defined human categories Cancer Epidemiology Biomarkers & Prevention 2020, 29: pr12-pr12. DOI: 10.1158/1538-7755.disp20-pr12.
- Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancersRozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, Blenman K, Ross JS, Rimm DL, Pusztai L. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers Journal For ImmunoTherapy Of Cancer 2020, 8: e001558. PMID: 33239417, PMCID: PMC7689582, DOI: 10.1136/jitc-2020-001558.
- PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast CancerAhmed FS, Gaule P, McGuire J, Patel K, Blenman K, Pusztai L, Rimm DL. PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer Clinical Cancer Research 2020, 26: 5456-5461. PMID: 32709714, PMCID: PMC7572612, DOI: 10.1158/1078-0432.ccr-20-1303.
- ISAC Probe Tag Dictionary: Standardized Nomenclature for Detection and Visualization Labels Used in Cytometry and Microscopy ImagingBlenman K, Spidlen J, Parks DR, Moore W, Treister A, Leif R, Bray C, Goldberg M, Force I, Brinkman R. ISAC Probe Tag Dictionary: Standardized Nomenclature for Detection and Visualization Labels Used in Cytometry and Microscopy Imaging Cytometry Part A 2020, 99: 103-106. PMID: 32881392, PMCID: PMC8388112, DOI: 10.1002/cyto.a.24224.
- Data File Standard for Flow Cytometry, Version FCS 3.2Spidlen J, Moore W, Parks D, Goldberg M, Blenman K, Cavenaugh JS, Force T, Brinkman R. Data File Standard for Flow Cytometry, Version FCS 3.2 Cytometry Part A 2020, 99: 100-102. PMID: 32881398, PMCID: PMC8241566, DOI: 10.1002/cyto.a.24225.
- Abstract 4973: Comparison of tumor immune microenvironment in triple negative breast cancer (TNBC) of African American versus that of white patientsYaghoobi V, Pelekanou V, O'Meara T, Silber A, Pusztai L, Rimm D, Blenman K. Abstract 4973: Comparison of tumor immune microenvironment in triple negative breast cancer (TNBC) of African American versus that of white patients Cancer Research 2020, 80: 4973-4973. DOI: 10.1158/1538-7445.am2020-4973.
- Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast CancersO’Meara T, Marczyk M, Qing T, Yaghoobi V, Blenman K, Cole K, Pelekanou V, Rimm DL, Pusztai L. Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers JCO Precision Oncology 2020, 4: po.19.00350. PMID: 32923897, PMCID: PMC7446500, DOI: 10.1200/po.19.00350.
- Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer.Iwase T, Pusztai L, Blenman K, Li X, Seitz R, Nielsen T, Schweitzer B, Hout D, Bailey D, Zhang X, Shen Y, Ueno N. Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer. Journal Of Clinical Oncology 2020, 38: 3117-3117. DOI: 10.1200/jco.2020.38.15_suppl.3117.
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancerKos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer Npj Breast Cancer 2020, 6: 17. PMID: 32411819, PMCID: PMC7217863, DOI: 10.1038/s41523-020-0156-0.
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working GroupAmgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Denkert C, Yuan Y, AbdulJabbar K, Wienert S, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J, Sebastian MM, Horlings HM, Hudeček J, Ciompi F, Moore DA, Singh R, Roblin E, Balancin ML, Mathieu MC, Lennerz JK, Kirtani P, Chen IC, Braybrooke JP, Pruneri G, Demaria S, Adams S, Schnitt SJ, Lakhani SR, Rojo F, Comerma L, Badve SS, Khojasteh M, Symmans WF, Sotiriou C, Gonzalez-Ericsson P, Pogue-Geile KL, Kim RS, Rimm DL, Viale G, Hewitt SM, Bartlett JMS, Penault-Llorca F, Goel S, Lien HC, Loibl S, Kos Z, Loi S, Hanna MG, Michiels S, Kok M, Nielsen TO, Lazar AJ, Bago-Horvath Z, Kooreman LFS, van der Laak JAWM, Saltz J, Gallas BD, Kurkure U, Barnes M, Salgado R, Cooper LAD. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group Npj Breast Cancer 2020, 6: 16. PMID: 32411818, PMCID: PMC7217824, DOI: 10.1038/s41523-020-0154-2.
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trialsHudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials Npj Breast Cancer 2020, 6: 15. PMID: 32436923, PMCID: PMC7217941, DOI: 10.1038/s41523-020-0155-1.
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer 2020, 6: 17. PMID: 33574291, DOI: 10.1038/s41523-020-0156-0.
- Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC)Pusztai L, Reisenbichler E, Bai Y, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Killelea B, Chagpar A, Frederick C, Burello T, Blenman K, Rimm D, Silber A. Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC) Cancer Research 2020, 80: pd1-01-pd1-01. DOI: 10.1158/1538-7445.sabcs19-pd1-01.
- Abstract P3-09-05: Predictive markers of response to durvalumab concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) neoadjuvant therapy for triple negative breast cancer (TNBC)Blenman K, Li X, Marczyk M, O'Meara T, Yaghoobi V, Gunasekharan V, Park T, Rimm D, Pusztai L. Abstract P3-09-05: Predictive markers of response to durvalumab concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) neoadjuvant therapy for triple negative breast cancer (TNBC) Cancer Research 2020, 80: p3-09-05-p3-09-05. DOI: 10.1158/1538-7445.sabcs19-p3-09-05.
- Abstract P4-10-14: Quantitative assessment of PD-L1 protein expression on macrophages and tumor cells as predictive markers of response to neoadjuvant durvalumab and chemotherapy in triple negative breast cancer (TNBC)Ahmed F, McGuire J, Gaule P, Blenman K, Pusztai L, Rimm D. Abstract P4-10-14: Quantitative assessment of PD-L1 protein expression on macrophages and tumor cells as predictive markers of response to neoadjuvant durvalumab and chemotherapy in triple negative breast cancer (TNBC) Cancer Research 2020, 80: p4-10-14-p4-10-14. DOI: 10.1158/1538-7445.sabcs19-p4-10-14.
- 185PD Immunological differences between immune-rich estrogen receptor-positive and -negative breast cancersO’Meara T, Marczyk M, Blenman K, Yaghoobi V, Pelenkanou V, Rimm D, Pusztai L. 185PD Immunological differences between immune-rich estrogen receptor-positive and -negative breast cancers Annals Of Oncology 2019, 30: v60-v61. DOI: 10.1093/annonc/mdz240.011.
- 012 Profiling immune cells using tissue cytometry and immune cell clustersBlenman K, Bosenberg M. 012 Profiling immune cells using tissue cytometry and immune cell clusters Journal Of Investigative Dermatology 2019, 139: s216. DOI: 10.1016/j.jid.2019.07.015.
- Quantitative assessment of immune cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC).O'Meara T, Yaghoobi V, Blenman K, Pelekanou V, Silber A, Rimm D, Pusztai L. Quantitative assessment of immune cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2019, 37: e14180-e14180. DOI: 10.1200/jco.2019.37.15_suppl.e14180.
- Pathology of B cell and neutrophil infiltration in the YUMMER1.7 mouse model of spontaneous melanoma tumor regressionBlenman K, Wang J, Cowper S, Bosenberg M. Pathology of B cell and neutrophil infiltration in the YUMMER1.7 mouse model of spontaneous melanoma tumor regression The Journal Of Immunology 2019, 202: 136.25-136.25. DOI: 10.4049/jimmunol.202.supp.136.25.
- Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic MelanomaWong PF, Wei W, Smithy JW, Acs B, Toki MI, Blenman K, Zelterman D, Kluger HM, Rimm DL. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma Clinical Cancer Research 2019, 25: 2442-2449. PMID: 30617133, PMCID: PMC6467753, DOI: 10.1158/1078-0432.ccr-18-2652.
- Pathology of spontaneous and immunotherapy‐induced tumor regression in a murine model of melanomaBlenman KRM, Wang J, Cowper S, Bosenberg M. Pathology of spontaneous and immunotherapy‐induced tumor regression in a murine model of melanoma Pigment Cell & Melanoma Research 2019, 32: 448-457. PMID: 30702217, PMCID: PMC6500596, DOI: 10.1111/pcmr.12769.
- Immune Cell and Cell Cluster Phenotyping, Quantitation, and Visualization Using In Silico Multiplexed Images and Tissue CytometryBlenman KRM, Bosenberg MW. Immune Cell and Cell Cluster Phenotyping, Quantitation, and Visualization Using In Silico Multiplexed Images and Tissue Cytometry Cytometry Part A 2018, 95: 399-410. PMID: 30468565, PMCID: PMC6500592, DOI: 10.1002/cyto.a.23668.
- Sentinel lymph node B cells can predict disease-free survival in breast cancer patientsBlenman KRM, He TF, Frankel PH, Ruel NH, Schwartz EJ, Krag DN, Tan LK, Yim JH, Mortimer JE, Yuan Y, Lee PP. Sentinel lymph node B cells can predict disease-free survival in breast cancer patients Npj Breast Cancer 2018, 4: 28. PMID: 30155518, PMCID: PMC6107630, DOI: 10.1038/s41523-018-0081-7.
- Abstract 3638: Quantitative assessment of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanomaWong P, Smithy J, Blenman K, Kluger H, Rimm D. Abstract 3638: Quantitative assessment of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma Cancer Research 2018, 78: 3638-3638. DOI: 10.1158/1538-7445.am2018-3638.
- 1245 PD-1 blockade impedes tumor growth in the immunogenic YUMMER1.7 mouse melanoma modelTurner N, Damsky W, Wang J, Meeth K, Blenman K, Bosenberg M. 1245 PD-1 blockade impedes tumor growth in the immunogenic YUMMER1.7 mouse melanoma model Journal Of Investigative Dermatology 2018, 138: s211. DOI: 10.1016/j.jid.2018.03.1260.
- UV‐induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma modelWang J, Perry CJ, Meeth K, Thakral D, Damsky W, Micevic G, Kaech S, Blenman K, Bosenberg M. UV‐induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model Pigment Cell & Melanoma Research 2017, 30: 428-435. PMID: 28379630, PMCID: PMC5820096, DOI: 10.1111/pcmr.12591.
- Correlation of sentinel lymph node immune cells with disease-free survival and metastasis in breast cancer patients using 4-color chromogen-based immunohistochemistry and quantitative imaging microscopyBlenman K. Correlation of sentinel lymph node immune cells with disease-free survival and metastasis in breast cancer patients using 4-color chromogen-based immunohistochemistry and quantitative imaging microscopy The Journal Of Immunology 2017, 198: 197.7-197.7. DOI: 10.4049/jimmunol.198.supp.197.7.
- A practical approach to high complexity multiplexed chromogenic immunohistochemistry.Blenman K. A practical approach to high complexity multiplexed chromogenic immunohistochemistry. The Journal Of Immunology 2016, 196: 69.19-69.19. DOI: 10.4049/jimmunol.196.supp.69.19.
- ISAC's Gating-ML 2.0 data exchange standard for gating description.Spidlen J, Moore W, ISAC Data Standards Task Force., Brinkman RR. ISAC's Gating-ML 2.0 data exchange standard for gating description. Cytometry A 2015, 87:683-7.
- ISAC's classification results file format.Spidlen J, Bray C, ISAC Data Standards Task Force., Brinkman RR. ISAC's classification results file format. Cytometry A 2015, 87:86-8.
- A two-layer structure prediction framework for microscopy cell detectionXu Y, Wu W, Chang EI, Chen D, Mu J, Lee PP, Blenman KR, Tu Z. A two-layer structure prediction framework for microscopy cell detection Computerized Medical Imaging And Graphics 2014, 41: 29-36. PMID: 25082065, DOI: 10.1016/j.compmedimag.2014.07.001.
- Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patientsRiess JW, Bhattacharya N, Blenman KR, Neal JW, Hwang G, Pultar P, Salcedo M, Engleman E, Lee PP, Malik R, Wakelee HA. Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients Immunopharmacology And Immunotoxicology 2014, 36: 182-186. PMID: 24494587, PMCID: PMC6464638, DOI: 10.3109/08923973.2013.864671.
- Quantitative and Spatial Image Analysis of Tumor and Draining Lymph Nodes Using Immunohistochemistry and High-Resolution Multispectral Imaging to Predict MetastasisBlenman KR, Lee PP. Quantitative and Spatial Image Analysis of Tumor and Draining Lymph Nodes Using Immunohistochemistry and High-Resolution Multispectral Imaging to Predict Metastasis 2013, 1102: 601-621. PMID: 24259001, DOI: 10.1007/978-1-62703-727-3_32.
- IL-10 regulation of lupus in the NZM2410 murine modelBlenman KR, Duan B, Xu Z, Wan S, Atkinson MA, Flotte TR, Croker BP, Morel L. IL-10 regulation of lupus in the NZM2410 murine model Laboratory Investigation 2006, 86: 1136-1148. PMID: 16924244, DOI: 10.1038/labinvest.3700468.
- Aberrant signaling in the TNFα/TNF receptor 1 pathway of the NZM2410 lupus-prone mouseBlenman KR, Bahjat FR, Moldawer LL, Morel L. Aberrant signaling in the TNFα/TNF receptor 1 pathway of the NZM2410 lupus-prone mouse Clinical Immunology 2004, 110: 124-133. PMID: 15003809, DOI: 10.1016/j.clim.2003.09.009.
- The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genesMorel L, Blenman K, Croker B, Wakeland E. The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes Proceedings Of The National Academy Of Sciences Of The United States Of America 2001, 98: 1787-1792. PMID: 11172029, PMCID: PMC29335, DOI: 10.1073/pnas.98.4.1787.
- Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strainsMorel L, Croker B, Blenman K, Mohan C, Huang G, Gilkeson G, Wakeland E. Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains Proceedings Of The National Academy Of Sciences Of The United States Of America 2000, 97: 6670-6675. PMID: 10841565, PMCID: PMC18697, DOI: 10.1073/pnas.97.12.6670.
- Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strainMorel L, Yu Y, Blenman KR, Caldwell RA, Wakeland EK. Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain Mammalian Genome 1996, 7: 335-339. PMID: 8661718, DOI: 10.1007/s003359900098.
Clinical Trials
Conditions | Study Title |
---|---|
Breast | Impact of obesity and sedentary lifestyles on immune response to and clinical outcomes of immunotherapies |